Drugs firm hails success as losses increase

A British company that develops cannabis-based medicines today said one of its drugs had been successful in treating multiple sclerosis as it posted slightly higher half-year losses.

GW Pharmaceuticals said tests had shown Sativex had significantly improved treatment of spasticity, or spasms and stiffness – one of the most common symptoms of MS.